CA-NEXTIVITY
15.3.2022 07:02:04 CET | Business Wire | Press release
Nextivity today announced that Nordic distributor Tura Scandinavia AB has the first European installation of Cel-Fi QUATRA 4000e underway. The new multi-carrier hybrid active DAS (distributed antenna system) for the EMEA market has been deployed at Elgiganten and Rusta stores in northern Stockholm, Sweden so customers and employees can now use their cell phones anywhere inside the stores, and experience good quality reception.
Spotty cellular coverage, poor voice quality, dropped calls, and dead zones continue to impact employees and customers in many retail buildings. Cel-Fi QUATRA 4000e is an affordable, all-digital, multi-carrier active DAS hybrid solution that solves this issue by providing uniform, high quality cellular signal throughout any commercial building. This industry-leading system is also carrier approved and guaranteed network safe.
“There was no cellular reception at all inside the Elgiganten and Rusta stores due to the metal construction of the buildings, which is common for commercial property in Sweden,” says Terje Skatterod, Senior Technology Officer at Tura Scandinavia, a Nordic distributor that offers mobile, data, and cellular equipment for retailers through a network of system integrators. “Cel-Fi QUATRA has improved the signal inside the stores by 25 dBM, which is equivalent to increasing the coverage by almost 100 times.”
“As Cel-Fi QUATRA is 5G-ready, building owners get a greater return on their investment with this modern solution which is upgradable,” explains Sverre Platou, Nextivity Brand Manager at Tura Scandinavia. “The system is also all-digital, using ethernet rather than coax cabling, which makes installation easier and reduces the installation cost to about a quarter of traditional repeater systems.”
“Cel-Fi QUATRA is starting to get a lot of attention in the Nordic region. Unlike other equipment, you don't need the RF skills to install it. You can simply use a local electrician to run the cabling and hook it up to the internet, and one telecom RF engineer to deploy the whole solution remotely,” Skatterod says.
Tura Scandinavia, which was named best European distributor in 2021 by Nextivity, has several installations of the new Cel-Fi QUATRA 4000e scheduled for other retailers in Sweden and throughout Europe. For more information about QUATRA, visit cel-fi.com/buy .
“Tura Scandinavia is a strong strategic partner for Nextivity, bringing our best-in-class cellular coverage solutions to the reseller community,” says David Cabanes, Nextivity Vice-President of European Sales. “With product offerings now available for enterprise, small and mid-size businesses, mobile, and micro solutions, we look forward to continuing to work with Tura Scandinavia to help their partners expand their capabilities and market reach.”
About Tura Scandinavia AB
Tura Scandinavia AB is a leading Nordic distributor of accessories in Audio, Video, Mobile, Data, Photography, TV, Gaming and SDA. Our philosophy is: a wide range, strong brands and fast delivery. The business was founded in Gothenburg in 1976 and we currently operate in Sweden, Denmark, Finland and Norway. The head office is located in Kungsbacka and the logistics center in Nässjö, Sweden.
About Nextivity
Headquartered in San Diego, Nextivity Inc. develops the award-winning, Cel-Fi family of products that deliver best-in-class connectivity for enterprise, business, residential spaces, and mobile cellular and public safety communication needs. Cel-Fi is the go-to solution for healthcare, government, hotels, retail, education, remote sites, parking garages, manufacturing, warehouses, as well as trucking and marine fleets. Cel-Fi products are available in 100 countries through mobile operators and a growing worldwide network of master distributors, systems integrators, installers, and resellers. Additional information is available at cel-fi.com , on Twitter , LinkedIn , and on Facebook .
Nextivity, the Nextivity logo, Cel-Fi, Smart Signal Booster, and Supercell are registered trademarks of Nextivity Incorporated in the United States and/or other countries. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005864/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom